cedazuridine,decitabine
otsuka
['mds', 'ascertain', 'astex pharma', 'taiho']
at #ash22, taiho oncology and astex announced data from the phase 3 ascertain trial that involved patients with mds who harbor tp53 mutations. read more: 
Our mission is to improve the lives of patients with cancer, their families, and their caregivers.